Although further experimental validation is needed to elucidate whether sorafenib or other drugs modulate TRAF3IP3‐mediated immune resistance via ERK/NFATC2/PD‐L1 signaling, the result once again confirms the reliability of our drug screening process based on the IGLoS score and the potential of TRAF3IP3 in glioma‐targeted therapies. This evidence concerns the gene TRAF3IP3 and central nervous system cancer.